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Aim: To investigate serum levels of MMP-2, TIMP-2, and MMP-2/TIMP-2 complex in epidermoid lung cancer and determine whether
one of these markers or any combination of them can be used as a prognostic factor and in the management of this disease.
Materials and methods: Twenty-eight patients with non-small cell lung cancer and 21 healthy, age-matched individuals participated in
this study. MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels were measured in the sera of the patients and controls with the ELISA
technique.
Results: MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels were significantly elevated in patients with non-small cell lung cancer
compared to the controls (P = 0.018, 0.041, and 0.034, respectively).
Conclusion: MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels increased not only in lung tissues, but in the sera of the patients
with non-small cell lung cancer. However, further studies are needed to fully evaluate the expression rates and diagnostic efficiency of
these parameters in different histopathological subtypes of this cancer and in prospective research with a large number of participants.
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Introduction
The Ministry of Health declared in 1997 that lung cancer
is the most frequent type of cancer in Turkey, accounting
for 17.6% of all cancer cases. Each year, lung cancer cases
comprise 15% of newly diagnosed cancer cases and cover
18% of cancer mortalities (1). The major cause of death in
lung cancer is metastasis as in other malignancies (2).
The extracellular matrix acts as a barrier against
tumor growth and invasion. Malignant tumors use
matrix metalloproteinases to skip over this barrier (3–6)
by degrading the extracellular matrix. MMPs are 28
extracellular proteases that play a role in physiological
and pathological tissue degradation. They are synthesized
from various epithelial and mesenchymal derived
cells, including leukocytes, keratinocytes, fibroblasts,
macrophages, chondrocytes, and smooth muscle cells.
Arthritis, inflammation, multiple sclerosis, chronic
wounds, chronic lung damage, bronchial asthma, and
pulmonary hypertension are the major pathologies in
which MMPs are involved apart than cancer (7). MMP-2
(gelatinase A) and MMP-9 (gelatinase B) are responsible
* Correspondence: oncel33@hotmail.com
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for degradation of Type IV collagen and were found to
be correlated with tumor aggressiveness and metastatic
potential (8–10).
Furthermore, tissue inhibitors of metalloproteinases
(TIMPs) play a pivotal role against the activity of MMPs
and distant site metastasis (11,12). To date, 4 types of these
inhibitors have been isolated in humans: TIMP-1, TIMP2, TIMP-3, and TIMP-4 (13,14). Both MMPs and TIMPs
have been investigated in lung cancers for diagnostic,
prognostic, and therapeutic purposes.
Non-small cell lung cancer (NSCLC) is the general
name of a broad cancer family with subgroups such
as epidermoid carcinoma (squamous cell carcinoma),
adenocarcinoma, and large cell carcinoma (15).
Epidermoid carcinoma accounts for about 30%–40% of
primary lung tumors. In this study, we aimed to investigate
the serum levels of MMP-2, TIMP-2, and MMP-2/TIMP2 complex in epidermoid lung cancer and to determine
whether one of these markers or any combination of them
can be used in the prognosis and management of this
disease.
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2. Materials and methods
2.1. Study groups
This study was performed in 28 patients (27 males, 1 female)
who were admitted to the pulmonary medicine and thoracic
surgery departments with the diagnosis of NSCLC based
on their physical examination, radiological findings, and
corresponding bronchoscopic and pathological evaluations.
A total of 21 healthy individuals (18 males, 3 females)
participated as the control group. Patients who were newly
diagnosed with NSCLC, lack of any other cancer history,
acute or chronic disease history, or permanent drug use
were included in the study. Blood samples were collected
before any radiotherapy or chemotherapy treatment.
Healthy individuals without an acute or chronic disease
history, permanent drug use, or smoking habit participated
in the study as the control group. The protocol of the study
was approved by the local ethics committee and informed
consent was obtained from all of the participants. The
demographical characteristics of the study groups are
shown in Table 1.
2.2. Biochemical analysis
Fasting venous blood samples were obtained from
all participants in the early morning and placed into
anticoagulant-free serum separator tubes and were
subsequently centrifuged at 2100 × g for 10 min at 4
°C. The serum portions were separated and transferred
into microtubes and stored at –60 °C until analysis.
Serum levels of MMP-2, TIMP-2, and MMP-2/TIMP2 were measured using the ELISA method. Quantikine
Human MMP-2 (R&D Systems, USA & Canada, Cat.

no: DMP200), Human TIMP-2 (RayBio, USA, Cat. no:
ELH-TIMP-001), and Human MMP-2/TIMP-2 (R&D
Systems, USA & Canada, Cat. no: DY 1497) kits were
used for circulating serum levels of MMP-2, TIMP-2, and
MMP-2/TIMP-2, respectively. The sensitivity levels of
these assays for MMP-2, TIMP-2, and MMP-2/TIMP-2
were 0.16 ng/mL, 10 pg/mL, and 25 pg/mL, respectively.
Briefly, aliquots of samples, standards, and controls were
added to antibody-coated microplate wells and incubated.
After aspiration and 4 washes, horseradish peroxidaseconjugated MMP-2, TIMP-2, or MMP-2/TIMP-2 complex
antibodies were added. This step was followed by sequential
incubation with substrate solution and stop solution. The
absorbances of each well were determined at 450 nm
(wavelength correction at 540 nm) using a microplate
reader. Quantitations were achieved by the construction of
standard curves using known concentrations of MMP-2,
TIMP-2, and MMP-2/TIMP-2 complex.
2.3. Statistical evaluation
SPSS 13 for Windows was used for statistical evaluation
of the data. The Shapiro–Wilk test was used to test the
distribution pattern of the numerical data and the Mann–
Whitney test was used to compare the medians between
the groups. The results were presented as median (min–
max). ROC curves were used to evaluate the diagnostic
efficiency of these parameters. The ability of these
parameters to distinguish cancer patients from healthy
individuals was tested with logistic regression analysis. P
< 0.05 was considered statistically significant.

Table 1. Demographic characteristics of the non-small cell lung cancer and control groups.
Parameter

Cancer

Control

Age (years)

53.75 ± 7.3

51.19 ± 7.34

Cigarettes (packs per year)

35 ± 13.54

N (female/male)
1/27
3/18

Histopathological type
Adenocancer

3 (10%)

Epidermoid cancer

25 (90%)

Stage
IB

2

IIB

4

IIIA

8

IIIB

7

IV

7
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3. Results
In our study, MMP-2, TIMP-2, and MMP-2/TIMP-2
complex levels were significantly higher in the cancer
group compared to the control group (Table 2). Subgroup
comparisons for different histopathological types of this
cancer could not be performed because almost all of
the cases were epidermoid carcinoma (n = 25). Because
almost of the cases were epidermoid cancer and since it is
the most common type of NSCLC we evaluated the data
and formulated our commentary and conclusions about
the levels of MMP-2, TIMP-2, and MMP-2/TIMP-2 in
epidermoid lung cancer.
There was no statistically significant difference between
the serum levels of these parameters for different stages of
the cancer. MMP-2 levels were 17.56 ± 3.73 and 18.07 ±
3.4 ng/mL, TIMP-2 levels were 6.51 ± 0.49 and 6.99 ± 0.54
ng/mL, and MMP-2/TIMP-2 complex levels were 1.02 ±
0.30 and 0.91 ± 0.31 ng/mL in stage I+II and stage III+IV,
respectively.
We performed ROC analysis and tested the diagnostic
efficiency of these parameters However, none of these
parameters ensured the required efficiency (P = 0.07,
0.08, and 0.06 for MMP-2, TIMP-2, and MMP-2/TIMP-2,
respectively).
In logistic regression analysis, only MMP-2 has limited
ability to distinguish epidermoid lung cancer cases from
the healthy ones (P = 0.055).
4. Discussion
In this study we measured serum levels of MMP-2, TIMP-2,
and MMP-2/TIMP-2 complex in epidermoid lung cancer.
MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels
were significantly higher in NSCLC patients compared to
the controls.
MMPs, the proteolytic enzymes of the extracellular
matrix, induce tumor invasion and the metastatic
process based on the facilitation of the angiogenesis and
degradation of extracellular matrix. However, MMPs’
tissue inhibitors have been reported to inhibit tumor

growth and invasion in NSCLC (16).
The results of the previous reports about MMPs in
NSCLCs are heterogeneous and vary from weak positivity
rates to significantly increased expression (16–20). Some
researchers reported no significant difference in MMP2 levels among different histopathological subtypes of
NSCLCs (17,20,21). On the other hand, some others
showed significantly higher levels of MMP-2 in squamous
cell carcinoma and adenocarcinoma (18,19,22). Our
results are consistent with the findings of these reports.
Because nearly almost of the cases were epidermoid cancer
we could not compare these parameters for different
histopathological subtypes.
Yurdakul et al. reported that 14.3% of their patients
were MMP-2 positive and 85.7% were negative among
NSCLC patients. Our results conflict with these findings.
It can be suggested that enzyme expression in tumor tissue
may not reflect the serum levels exactly.
There are conflicting reports about the relation between
MMPs and stage of NSCLCs (23). Some reports suggested
that no relationship exists between stage of cancer and
MMP-2 levels in NSCLCs (19,22,24,25). Other researchers
detected a significant association between stage and MMP2 expression (17,18,21,25). We did not find a significant
difference for serum levels of MMP-2 among different
stages of the cancer.
The results of studies on TIMP-2 expression in
NSCLCs are heterogeneous. The expression rates vary
from 45% to 82% (16,22,26). Although we and many
other authors demonstrated that TIMP-2 levels were
increased in NSCLCs, Suemitsu et al. reported that TIMP1 levels were elevated in NSCLC patients while TIMP-2
levels were decreased (27). They interpreted these results
as showing that the reaction of immunohistochemical
staining for TIMP-2 was mild in areas of in situ and
invasive carcinoma, whereas the reaction was stronger
in the basal cells at the interfaces between areas of basal
cell hyperplasia or squamous metaplasia and dysplasia or
carcinoma in situ. They concluded that TIMP-2 levels in

Table 2. Serum levels of MMP-2, TIMP-2, and MMP-2/TIMP-2 in the cancer and control groups.
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Parameter

Cancer
(median, min–max)

Control
(median, min–max)

P

MMP-2 (ng/mL)

17.75 (13.43–28.46)

16.23 (8.06–18.97)

0.018

TIMP-2 (ng/mL)

6.97 (5.31–8)

6.569 (4.31–7.98)

0.041

MMP-2/TIMP-2
complex (ng/mL)

0.88 (0.53–1.8)

0.73 (0.46–1.14)

0.034
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their patients with NSCLC were low because of the lowgrade histological type.
The authors of previous reports are not in agreement
about the impact of the histopathological subtype or
the stage. Some researchers declared that there was no
statistically significant association between histological
subtype and TIMP-2 levels in NSCLCs (22,25,28).
However, Albelda et al. reported that the difference in
TIMP-2 levels was significant during the transformation
of the metaplastic epithelium to SCC (29). In a recent
article, it was demonstrated that the expression of TIMP1 and TIMP-2 was higher in adenocarcinoma than in
squamous cell carcinoma (30). Similarly, the results
interpreting the effect of the tumor stage on TIMP-2 levels
are conflicting. There are reports suggesting that the stage
has no significant effect on TIMP levels (22,25). However,
some authors demonstrated that the expression of TIMP-1
levels was correlated with tumor stage and patient survival
data (28,31). We did not find any significant difference
for serum levels of TIMP-2 among different stages of
the cancer. We measured MMP-2, TIMP-2, and MMP2/TIMP-2 levels in order to evaluate which one of these
parameters would be more beneficial in distinguishing
epidermoid lung cancer cases from the healthy ones and to
test the diagnostic efficiency of these parameters. However,
none of these parameters ensured the required efficiency.
In logistic regression analysis, only MMP-2 presented
limited ability to distinguish epidermoid lung cancer cases
from the healthy ones.
Our study demonstrated that serum MMP-2, TIMP2, and MMP-2/TIMP-2 complex levels were significantly
elevated in patients with epidermoid subtype of NSCLC
compared to the control group. Our findings indicating
increased levels of both free and complex forms of MMP2 with its tissue inhibitor TIMP-2 are in agreement
with previous reports suggesting that epidermoid
cancer invades and metastasizes by extracellular matrix
degradation (3,8,9).
Because of the pattern of our study group (almost of
the cases were epidermoid cancer) we could not make
an evaluation and comment about MMPs, TIPMs, and
MMP/TIPM complexes among different histopathological
subtype of NSCLC.
Similarly, our results are in agreement with previous
reports suggesting that the stage of the tumor also had no
effect on either MMPs or TIMPs in NSCLCs.
There are few studies in the available literature
evaluating both MMPs and TIMPs in lung cancer and
most of them were performed in small cell lung cancer.
Michael et al. investigated MMP-1, MMP-2, MMP-3,
MMP-9, MMP-11, MMP-13, and MMP-14 and TIMP-1,
TIMP-2, TIMP-3, and TIMP-4 expressions in small cell
lung cancer using the immunohistochemical technique

and demonstrated that their productions had increased
at alternating rates in the tumor tissues (32). There are
also a few reports that have evaluated both MMP-2 and
TIMP-2 in NSCLC. Eren et al. also demonstrated through
immunohistochemistry that tissue expressions of MMP2 and TIMP-2 were increased in patients with NSCLC
(25). In another study, it was demonstrated that MMP-2,
MMP-9, and TIMP-1 levels were elevated, while TIMP2 levels were decreased in tumor tissues compared to
normal tissues in NSCLC (26). In our study, TIMP-2 levels
were increased in epidermoid lung cancer. Our results
are in agreement with the results reported by Eren et al.
We suggest that the higher percentage of advanced stage
cancer cases might be the cause of the higher TIMP-2
levels. In a recent article, expression of MMP-2, TIMP-1,
and TIMP-2 was evaluated and it was suggested that all of
these parameters were higher in adenocarcinoma than in
squamous cell carcinoma (30). Lim et al. also measured
the expression levels of both MMP-2 and TIMP-1 and
reported that they were correlated with tumor stage and
patient survival data (31).
Most authors who measured the levels of MMP-2 and
TIMP-2 in lung cancer reported their concentrations at
tissue levels (16-26). There are 2 reports in the literature
evaluating the serum levels of MMP-2 and TIMP-2 in lung
cancer patients. Garbisa et al. measured MMP-2 levels
in the serum of lung cancer patients and observed that
serum levels increased with advancing stages and were
significantly increased in patients in stage IV compared
to the control group (33). We did not find any significant
difference between the serum levels of MMP-2 among
different stages of epidermoid cancer.
Ylisirniö et al. detected serum MMP-2, MMP-9, TIMP1, and TIMP-2 levels as prognostic markers and also
MMP-2/TIMP-2 complex levels in order to demonstrate
both free and complex forms of MMP-2. Conflicting with
the previous reports and our data, they suggested that both
serum TIMP-2 and MMP-2/TIMP-2 complex levels were
decreased in cancer patients compared to healthy ones
(28). In our study, MMP-2, TIMP-2, and MMP-2/TIMP-2
complex levels were increased in epidermoid lung cancer
compared to the healthy controls. It can be suggested
that MMP-2/TIMP-2 complex levels also increase as
a tissue defense mechanism and this accompanies the
overproduction of these enzymes involved in tissue
degradation.
The underlying mechanisms of the increased expression
of MMPs and TIMPs in NSCLC are still unclear. It had been
suggested that TIMP-2 prevented the proliferation and
invasion of cancer cells by inhibiting MMP-2. However,
Bourboulia et al. observed that TIMP-2-mediated
inhibition of tumor growth occurs independently of
MMP inhibition and is caused by both the direct effects
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of TIMP-2 on tumor cells and modulation of the tumor
microenvironment (34); but it is known that MMP-2 can
also be inhibited by TIMP-2, not only by TIMP-2.
We measured both free and complex forms of MMP-2
and TIMP-2 to determine whether one of these markers
or any combination of them can be used in the prognosis
and management of this disease. We observed that both
of the free fractions, as well as the complex form, were
significantly increased. In ROC analysis the diagnostic
efficiency of these parameters was tested, but none of these
parameters ensured the required efficiency. According to
logistic regression analysis results, only MMP-2 has limited
ability to distinguish epidermoid lung cancer cases from
healthy ones. In epidermoid lung cancer overproduction
of MMP-2/TIMP-2 complex levels accompanies the
overproduction of MMP-2. This can be explained by the
defense mechanism of the tissue. It can also be suggested
that any of these parameters can be used for monitoring
the response to therapy and prognostic evaluation of the
patient with this type of cancer. However, none of these
parameters achieved the sufficient diagnostic specificity
and sensitivity.
The small number of patients in the study group was the
major limitation of our study. We would have compared
the levels of these parameters in different histopathological
types and we would have probably demonstrated the
diagnostic efficiency of one or more of these parameters if

a higher number of participants had been included in the
study.
Expression of MMPs and TIMPs in tumor tissues
was determined with immunohistochemistry, in situ
hybridization, RT-PCR, and zymography (16–27). We
measured serum levels and used the ELISA technique in
our study. Our results are almost parallel with the results
obtained at the tissue level. Serum analysis of these data
is non-invasive and the ELISA technique is simple, easy
to perform, economical, and suitable for routine analysis.
We suggest that MMP-2, TIMP-2, and MMP-2/TIMP2 complex levels are elevated not only in lung tissues but
also in the sera of the patients with NSCLC. Measurement
of MMPs and their tissue inhibitors in the sera of patients
is easier and more practical than determining them in
tissue samples, which can be obtained only by invasive
procedures such as bronchoscopy or surgery. Measuring
the serum levels of these parameters will also provide the
clinician with information about the expression rates of
MMPs and TIMPs and be sufficient to formulate an idea
about the proteolytic characteristics of non-small cell
tumors. However, further studies with a larger number
of participants are needed to perform a full evaluation of
the expression rates and ensure the diagnostic efficiency of
these parameters in different histopathological subtypes of
lung cancer.
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